Officer and Director Transactions Report

This filing details transactions made by Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, Inc. On April 6, 2026, Doyle acquired 3,970 shares of Common Stock through the exercise of a stock option at a price of $12.65 per share, increasing their post-transaction holdings to 7,592 shares. Concurrently, Doyle disposed of 3,970 shares of Common Stock at prices ranging from $18.00 to $18.10, resulting in post-transaction holdings of 3,622 shares. These transactions were executed under a Rule 10b5-1 trading plan. The stock option, which has an exercise price of $12.65, vests over time, with a portion vesting on July 15, 2025, and the remainder vesting monthly over the subsequent three years, contingent upon continued service.